Compare

Embla Medical hf./DKr EMBLA

1D1W1M3M6MYTD1Y5YMAX

About Embla Medical hf.

Embla Medical hf., headquartered in Reykjavik, Iceland, specializes in non-invasive orthopedic products, focusing on prosthetics, neuro orthotics, bracing, and supports. The company operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. Its product portfolio includes mechanical and bionic prosthetic devices, bracing solutions for various body parts, and patient care services for individuals with limb loss or musculoskeletal conditions. Originally founded as Össur hf. in 1971, the company rebranded to Embla Medical hf. in April 2024 to reflect its expanded scope and unified purpose. Embla Medical serves a global market, with operations across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's strategic positioning is strengthened by its diverse brand portfolio, including Össur, Fior & Gentz, College Park, and ForMotion, enabling it to offer comprehensive mobility solutions worldwide.
Ticker
DKr EMBLA
Sector
Health
Primary listing
CSE
Employees
4,500
Headquarters
Reykjavik, Iceland
Website
www.emblamedical.com

EMBLA Metrics

BasicAdvanced
kr 12B
18.98
kr 1.49
0.46
-

What the Analysts think about EMBLA

Analyst ratings (Buy, Hold, Sell) for Embla Medical hf. stock.
Analyst projections of the future price of Embla Medical hf. stock.

Bulls say / Bears say

Prosthetics & Neuro Orthotics remains a growth engine: organic sales rose 7% in Q3, led by strong EMEA demand. This helps offset slower growth elsewhere in the business. (Embla Medical)
Profitability and cash generation have held up despite softer sales: Q3 EBITDA margin stayed at 22%, nine-month free cash flow rose 13%, and leverage was 2.1 times EBITDA. The company also continued share buy-backs. (Embla Medical)
Recent product launches and development work could support future growth. Embla launched six products in Q2 and said its prototype microprocessor knee for less-mobile users remained on track for a late-2027 launch. (Embla Medical)
Sales momentum has slowed: Q3 organic growth was 4%, and Embla cut its 2026 growth outlook to about 5% from a previous 5–7% range. It also narrowed its expected EBITDA margin to about 21%. (Embla Medical)
Patient Care remains a weak spot, with sales flat in Q3 and below management’s expectations. The company said integration work in selected regions had slowed its ability to grow patient volumes. (Embla Medical)
Near-term manufacturing costs are pressuring gross margins: the Q3 margin fell to 62% from 63% a year earlier as Embla optimised some smaller prosthetics sites. The work is intended to improve efficiency over time, but the benefit has yet to arrive. (Embla Medical)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.

EMBLA Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

EMBLA Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.